Access cutting-edge huntington's disease treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.
Access huntington's disease specialists in Ann Arbor at no cost
This study follows strict safety protocols and ethical guidelines
All study-related huntington's disease treatment provided free
This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase 1/2, multicenter, first-in-human (FIH) study. The first three cohorts of the study have completed enrollment, including the randomized, double-blind, sham-controlled cohorts. Cohort 4 is open-label. Cohort 4 participants will receive high dose AMT-130.
Sponsor: UniQure Biopharma B.V.
Check if you qualify for this huntington's disease clinical trial in Ann Arbor, MI
If you're searching for huntington's disease treatment options in Ann Arbor, MI, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced huntington's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.